# Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)

Source: https://welltoldgrants.com/grants/par-23-195-simultaneous-and-synergistic-multi-target-validation-for/  
Official notice: https://www.grants.gov/search-results-detail/348829

> National Institutes of Health offered grants of up to $499,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 15, 2023.

| Field | Value |
|---|---|
| Opportunity number | PAR-23-195 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | September 15, 2023 |
| Award ceiling | $499,000 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.853, 93.866 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

## What the grant funds

The ultimate goal is to develop multi-target disease-modifying therapeutics based on an appreciation of the complex interaction of pathways, cells, circuits, systems or pathologies that are present in complex AD/ADRD diagnoses. Such therapeutics could be a single drug or biologic targeting multiple pathways, cell, circuits, systems or pathologies, or could be a combination of therapies. While hundreds of possible targets have been suggested for AD alone, theres a need to better understand how multiple targets might interact in a synergistic way that would allow us to tackle AD/ADRD from multiple fronts in a single person, akin to what has been successful in infectious disease or cancer. This FOA will support applications that test hypotheses of possible beneficial interactions of known targets as well as understanding the mechanisms of interaction in the R61. The R33 would support rigorous validation of the proposed multi-target approach (one drug or biologic targeting multiple pathways; and/or a combination of therapies) to support future multi-target therapy development efforts. Successful grantees will be in position to apply for IGNITE or other similar translational grant mechanisms.

## Questions people ask

### Is PAR-23-195 still open?

No. It closed on September 15, 2023.

### Who can apply for Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)?

Closed September 15, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $499,000 each.

### Who has been funded under PAR-23-195?

NIH RePORTER lists 1 project funded under PAR-23-195 in fiscal 2024, at 1 institution.

### Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before?

The largest recipients over five fiscal years were The General Hospital Corporation, The Regents of the University of California, San Francisco, The Johns Hopkins University. The program made 8,641 awards worth $9.1 billion in that time.